Why the study?
Is transapical aortic valve implantation using a novel low-profile delivery system safe and effective in patients with severe symptomatic aortic stenosis and high surgical risk ineligible for transfemoral access?
Is transapical aortic valve implantation using a novel low-profile delivery system safe and effective in patients with severe symptomatic aortic stenosis and high surgical risk ineligible for transfemoral access?
A novel low-profile transapical delivery system for TAVI demonstrated high procedural success and acceptable safety at 6 months in high-risk patients ineligible for transfemoral access.
No takes yet. Share an insight, caveat, or question.
Feasibility of novel 22-Fr transapical system supported in high-risk non-transfemoral patients; leaves open randomized confirmation of outcomes.
Conradi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: